Author: admin

Postpartum Depression Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb

The Key Postpartum Depression Companies in the market include – SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, and others.

 

DelveInsight’s “Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Postpartum Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postpartum Depression Market Forecast

 

Some of the key facts of the Postpartum Depression Market Report

  • The Postpartum Depression market size was valued ~USD 260 million in 2023 among the 7MM countries and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In March 2025, Lipocine has initiated a randomized Phase III clinical trial for LPCN 1154, an oral formulation of brexanolone designed to treat postpartum depression (PPD). The trial follows a pharmacokinetic bridge study, which compared LPCN 1154’s exposure to that of the reference drug. The company expects to dose the first participant in the second quarter of this year.

  • In May 2024, Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, announced today the completion of subject dosing in the pivotal pharmacokinetic (PK) study intended to support a New Drug Application (NDA) for LPCN 1154. LPCN 1154, an oral formulation of brexanolone, is being developed as a treatment for postpartum depression (PPD).

  • Among the EU4 countries and the UK, the UK had the largest market size for Postpartum Depression, estimated at approximately USD 25 million in 2023.

  • By 2034, ZURZUVAE is anticipated to generate approximately USD 600 million in revenue from the postpartum depression therapeutics market across the 7MM.

  • Among the EU4 countries and the UK, the UK had the largest postpartum depression market size, approximately USD 25 million in 2023.

  • In 2023, Japan’s postpartum depression market size was approximately USD 20 million, with a moderate growth expected by 2034.

  • In 2023, the total number of diagnosed postpartum depression cases across the seven major countries was approximately 1,310,000.

  • In 2023, the total number of diagnosed postpartum depression cases in the EU4 countries and the UK was approximately 460,000.

  • In 2023, the United States had the highest number of diagnosed postpartum depression cases among the seven major markets, totaling approximately 720,000, followed by the UK.

  • In 2023, Japan had approximately 126,000 diagnosed prevalent cases of postpartum depression.

  • ZURZUVAE (zuranolone) and ZULRESSO (brexanolone) are the only approved treatments for postpartum depression (PPD). ZULRESSO is given as a continuous intravenous (IV) infusion, while the recommended dosage for ZURZUVAE is 50 mg taken orally for 14 days. Leading companies working on new PPD therapies include Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, and Brii Biosciences.

  • Key Postpartum Depression Companies: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, and others

  • Key Postpartum Depression Therapies: Zuranolone(SAGE-217), BRII-296, RE104, GH001, Brexanolone, aripiprazole, and others

  • The Postpartum Depression epidemiology based on gender analyzed that PPD majorly affects females but a small proportion of males can also experience depression post-pregnancy

  • The Postpartum Depression market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Postpartum Depression pipeline products will significantly revolutionize the Postpartum Depression market dynamics.

 

Postpartum Depression Overview

Postpartum depression (PPD) is a complex emotional and psychological condition that affects women after childbirth. It typically occurs within the first few weeks to months following delivery and is characterized by feelings of extreme sadness, anxiety, and fatigue, which can significantly impact a mother’s ability to care for herself and her baby.

 

Get a Free sample for the Postpartum Depression Market Report:

https://www.delveinsight.com/report-store/postpartum-depression-ppd-market

 

Postpartum Depression Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Postpartum Depression Epidemiology Segmentation:

The Postpartum Depression market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Postpartum Depression

  • Prevalent Cases of Postpartum Depression by severity

  • Gender-specific Prevalence of Postpartum Depression

  • Diagnosed Cases of Episodic and Chronic Postpartum Depression

 

Download the report to understand which factors are driving Postpartum Depression epidemiology trends @ Postpartum Depression Epidemiology Forecast

 

Postpartum Depression Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postpartum Depression market or expected to get launched during the study period. The analysis covers Postpartum Depression market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Postpartum Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Postpartum Depression Therapies and Key Companies

  • Zuranolone(SAGE-217): SAGE Therapeutics

  • BRII-296: Brii Biosciences Limited

  • RE104: Reunion Neuroscience

  • GH001: GH Research

  • Brexanolone: Sage Therapeutics

  • aripiprazole: Bristol-Myers Squibb

 

Discover more about therapies set to grab major Postpartum Depression market share @ Postpartum Depression Treatment Market

 

Postpartum Depression Market Drivers

  • ZULRESSO starts working within 2–3 days of the administration, drastically improving the response rates compared to conventional therapies

  • Therapies like BRII-296 and LPCN-1154 are in early stages of clinical development and their approval in future can help the PPD therapeutic market grow tremendously.

 

Postpartum Depression Market Barriers

  • Limited therapies are available for treating and diagnosing PPD, thus providing profitable opportunities for emerging therapies

  • Increasing research and development to establish the pathophysiology and recent advancement in the diagnosis gives alucrative opportunity for the PPD market

 

Scope of the Postpartum Depression Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Postpartum Depression Companies: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, and others

  • Key Postpartum Depression Therapies: Zuranolone(SAGE-217), BRII-296, RE104, GH001, Brexanolone, aripiprazole, and others

  • Postpartum Depression Therapeutic Assessment: Postpartum Depression current marketed and Postpartum Depression emerging therapies

  • Postpartum Depression Market Dynamics: Postpartum Depression market drivers and Postpartum Depression market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Postpartum Depression Unmet Needs, KOL’s views, Analyst’s views, Postpartum Depression Market Access and Reimbursement

 

To know more about Postpartum Depression companies working in the treatment market, visit @ Postpartum Depression Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Postpartum Depression Market Report Introduction

2. Executive Summary for Postpartum Depression

3. SWOT analysis of Postpartum Depression

4. Postpartum Depression Patient Share (%) Overview at a Glance

5. Postpartum Depression Market Overview at a Glance

6. Postpartum Depression Disease Background and Overview

7. Postpartum Depression Epidemiology and Patient Population

8. Country-Specific Patient Population of Postpartum Depression

9. Postpartum Depression Current Treatment and Medical Practices

10. Postpartum Depression Unmet Needs

11. Postpartum Depression Emerging Therapies

12. Postpartum Depression Market Outlook

13. Country-Wise Postpartum Depression Market Analysis (2020–2034)

14. Postpartum Depression Market Access and Reimbursement of Therapies

15. Postpartum Depression Market Drivers

16. Postpartum Depression Market Barriers

17. Postpartum Depression Appendix

18. Postpartum Depression Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Postpartum Depression Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb

Fabry Disease Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics

The Key Fabry Disease Companies in the market include – Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others.

 

DelveInsight’s “Fabry Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Fabry Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fabry Disease Market Forecast

 

Some of the key facts of the Fabry Disease Market Report:

  • The Fabry Disease market size was valued ~USD 1,700 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In May 2025, All patients treated with Sangamo Therapeutics’ gene therapy candidate ST-920 (isaralgagene civaparvovec) for Fabry disease in a Phase 1/2 trial have now reached the FDA’s required one-year milestone to proceed toward accelerated approval. According to Sangamo’s recent update, a pivotal data readout is anticipated by the end of June. The FDA previously indicated that data from the ongoing Phase 1/2 STAAR trial (NCT04046224) could be sufficient for accelerated approval, potentially eliminating the need for further clinical trials and speeding the therapy’s market entry.

  • In March 2025, Sangamo Therapeutics announced its agreement with the FDA on pursuing an accelerated approval pathway for ST-920 in Fabry disease, with a Biologics License Application (BLA) planned for submission in the latter half of 2025.

  • In February 2025, Isaralgagene civaparvovec (ST-920) is an experimental gene therapy designed to lower the abnormal buildup of specific fatty substances and potentially slow or stop the progression of Fabry disease. Developed by Sangamo Therapeutics, this therapy is intended to be administered through a single intravenous (IV) infusion. The U.S. Food and Drug Administration (FDA) has granted it Fast Track designation, Orphan Drug status, and Regenerative Medicine Advanced Therapy (RMAT) designation, recognizing its potential to address a serious unmet medical need.

  • In February 2025, Amicus Therapeutics shared updates on its migalastat development programs through oral presentations and poster sessions at the 21st Annual WORLD Symposium 2025.

  • In December 2024, Exegenesis Bio, a global clinical-stage gene therapy company, announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to EXG110, an innovative gene therapy for Fabry disease—a rare lysosomal disorder characterized by excessive lipid accumulation in tissues, leading to renal failure, cardiac complications, and strokes.

  • In 2024, the United States held the largest share of the Fabry Disease Therapeutics Market among the 7MM, with an estimated value of around USD 880 million. This market is projected to grow at a notable compound annual growth rate (CAGR) over the forecast period from 2020 to 2034.

  • In 2024, Germany recorded the largest Fabry Disease Treatment Market Size among European countries, reaching approximately USD 210 million. In contrast, Spain had the smallest market size, with an estimated value of around USD 82 million.

  • In 2024, Japan’s Fabry Disease Therapeutics Market Size was estimated at approximately USD 150 million, representing around 9% of the overall market across the 7MM.

  • The anticipated introduction of upcoming therapies like ST-920 is expected to drive changes in the overall Fabry Disease market size in the coming years.

  • In 2024, the total number of diagnosed prevalent cases of Fabry Disease in the United States was estimated to be approximately 9,200.

  • In 2024, the United States accounted for the largest share of the diagnosed prevalent population of Fabry Disease, representing approximately 52% of the total across the 7MM. Meanwhile, the combined share of EU4 and the UK made up around 38%, and Japan contributed roughly 10% of the total diagnosed population.

  • In 2024, among the EU4 countries and the UK, Germany had the highest number of diagnosed prevalent Fabry Disease cases (around 2,170), followed by the UK, while Spain reported the lowest number of cases.

  • In 2024, the estimated number of diagnosed prevalent cases in the US included approximately 3,300 individuals with the classic phenotype and around 5,860 with the late-onset phenotype.

  • Key Fabry Disease Companies: Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others

  • Key Fabry Disease Therapies: ELFABRIO (PRX-102), Venglustat, Isaralgagene civaparvovec (ST-920), PRX-102, AVR-RD-01, Venglustat, ST -920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others

  • The Fabry Disease epidemiology based on gender analyzed that Fabry Disease is more prevalent in males than females in the United States

  • The Fabry Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fabry Disease pipeline products will significantly revolutionize the Fabry Disease market dynamics.

 

Fabry Disease Overview

Fabry disease is a rare genetic disorder caused by mutations in the GLA gene, which leads to a deficiency or malfunction of the enzyme alpha-galactosidase A. This enzyme is crucial for breaking down a fatty substance called globotriaosylceramide (Gb3 or GL-3) in the body’s cells. When alpha-galactosidase A is deficient or dysfunctional, Gb3 accumulates in various tissues and organs, leading to a wide range of symptoms.

 

Get a Free sample for the Fabry Disease Market Report:

https://www.delveinsight.com/report-store/fabry-disease-market

 

Fabry Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Fabry Disease Epidemiology Segmentation:

The Fabry Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Fabry Disease

  • Prevalent Cases of Fabry Disease by severity

  • Gender-specific Prevalence of Fabry Disease

  • Diagnosed Cases of Episodic and Chronic Fabry Disease

 

Download the report to understand which factors are driving Fabry Disease epidemiology trends @ Fabry Disease Epidemiology Forecast

 

Fabry Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fabry Disease market or expected to get launched during the study period. The analysis covers Fabry Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fabry Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Fabry Disease Therapies and Key Companies

  • ELFABRIO (PRX-102): Chiesi and Protalix Biotherapeutics

  • Venglustat: Sanofi Genzyme

  • Isaralgagene civaparvovec (ST-920): Sangamo Therapeutics

  • PRX-102: Protalix Biotherapeutics

  • AVR-RD-01: AVROBIO

  • Venglustat: Sanofi Genzyme

  • ST-920: Sangamo Therapeutics

  • FLT190: Freeline Therapeutics

  • 4D-310: 4D Molecular Therapeutics

  • Lucerastat: Idorsia Pharmaceuticals

  • Moss-aGal: Greenovation Biotech GMBH

  • PRX-102: ICON plc

  • pegunigalsidase alfa: Chiesi Farmaceutici S.p.A.

  • migalastat: Amicus Therapeutics

  • Agalsidase alfa: Shire

 

Discover more about therapies set to grab major Fabry Disease market share @ Fabry Disease Treatment Market

 

Fabry Disease Market Strengths

  • Emphasis on NBS to detect Fabry Disease at an early stage allows for timely treatment with better risk- benefit assessment.

  • The growing Fabry Disease pool is expected to propel the treatment market, adding opportunities for new pharma players.

 

Fabry Disease Market Opportunities

  • Development of potential biomarkers allows tracking the severity and predicting the progression of the disease, as well as checking the effectiveness of therapeutic intervention.

  • The shortcomings of enzyme replacement therapy, partly due to antibody formation, can be alleviated by combining new oral therapy approaches.

 

Scope of the Fabry Disease Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Fabry Disease Companies: Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others

  • Key Fabry Disease Therapies: ELFABRIO (PRX-102), Venglustat, Isaralgagene civaparvovec (ST-920), PRX-102, AVR-RD-01, Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others

  • Fabry Disease Therapeutic Assessment: Fabry Disease current marketed and Fabry Disease emerging therapies

  • Fabry Disease Market Dynamics: Fabry Disease market drivers and Fabry Disease market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Fabry Disease Unmet Needs, KOL’s views, Analyst’s views, Fabry Disease Market Access and Reimbursement

 

To know more about Fabry Disease companies working in the treatment market, visit @ Fabry Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Fabry Disease Market Report Introduction

2. Executive Summary for Fabry Disease

3. SWOT analysis of Fabry Disease

4. Fabry Disease Patient Share (%) Overview at a Glance

5. Fabry Disease Market Overview at a Glance

6. Fabry Disease Disease Background and Overview

7. Fabry Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Fabry Disease

9. Fabry Disease Current Treatment and Medical Practices

10. Fabry Disease Unmet Needs

11. Fabry Disease Emerging Therapies

12. Fabry Disease Market Outlook

13. Country-Wise Fabry Disease Market Analysis (2020–2034)

14. Fabry Disease Market Access and Reimbursement of Therapies

15. Fabry Disease Market Drivers

16. Fabry Disease Market Barriers

17. Fabry Disease Appendix

18. Fabry Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fabry Disease Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics

AV Access Launches BizEye P30: A 4K Dual-Lens PTZ Conference Camera with AI Tracking for Smarter Hybrid Meetings

“”The BizEye P30 is designed to bring clarity, intelligence, and simplicity to hybrid meetings,” said Bill Liao, CTO of AV Access. “With dual-lens coverage and smart AI tracking, it ensures every participant is seen clearly—no matter where they sit or how they move.””
AV Access introduces the BizEye P30, an advanced 4K dual-lens PTZ conference camera designed to elevate video conferencing in small to medium-sized meeting rooms. With panoramic and zoom lenses, AI-powered framing, and plug-and-play simplicity, the BizEye P30 delivers crystal-clear visuals and intelligent tracking—ideal for hybrid meetings, online education, and remote collaboration.

AV Access, a leading provider of Pro AV and AV over IP solutions, proudly announces the release of the BizEye P30 4K dual-lens PTZ camera. Engineered for modern meeting spaces, the BizEye P30 combines a panoramic wide-angle lens with a PTZ zoom lens, offering both full-room coverage and detailed close-ups. With support for 4K@30Hz resolution, 3x optical zoom, and AI-powered modes, it ensures every participant is clearly seen—whether presenting, collaborating, or attending remotely.

Dual-Lens Design for Full-Room Coverage and Precision Focus

The BizEye P30 features a 120° panoramic lens to capture the entire room and a 110° PTZ lens with 3x optical zoom for dynamic close-ups. This dual-lens system allows the camera to switch seamlessly between wide-angle views and focused framing, ensuring that both group discussions and individual speakers are presented with clarity.

“Equipped with an 8MP CMOS sensor, the camera delivers sharp, vibrant video even in challenging lighting conditions. Whether mounted above a display, below it, or on a wall, the BizEye P30 offers flexible installation and plug-and-play setup via USB—making it easy to integrate into any meeting room,” explained Bill Liao, CTO at AV Access.

Smarter Meetings with AI Tracking and Presenter Modes

Designed to make meetings more engaging and efficient, the BizEye P30 includes AI-powered features such as:

* Individuals Gallery: Automatically detects and frames up to four participants individually, ideal for hybrid meetings.

* Presenter Tracking: Keeps the speaker in focus as they move around the room.

* Auto Framing: Adjusts the view to include all participants when more than four are detected.

Users can switch modes or adjust the camera angle using the included IR remote control, staying in full control without leaving their seat. When not in use, the camera enters privacy mode, tilting the lens downward to protect user privacy.

“The BizEye P30 is now available for pre-order on AV Access’s official website at a special launch price of $239.99—20% off the regular price,” concluded Bill. “It complements our expanding lineup of hybrid conferencing solutions, including the eShare W90 wireless conferencing system and AnyCo series speakerphones.”

About AV Access

AV Access is a global leader in Pro AV and AV over IP solutions, offering a diverse range of products, including HDMI/KVM extenders, splitters, switchers, KVM switches, AV over IP solutions, and wireless conferencing systems. Since its inception, the company has been committed to delivering high-quality AV products at competitive pricing, providing seamless audiovisual experiences for users worldwide.

AV Access continues to innovate, developing cutting-edge solutions for smart home, corporate, education, retail, entertainment, healthcare, and more. Backed by a strong R&D team, a robust supply chain, and an expert management team, AV Access is a trusted partner in AV technology. Learn more at www.avaccess.com.

Media Contact
Company Name: Actions Global (US) Inc
Contact Person: Shane Jiang
Email: Send Email
Phone: +1-866-629-3923
Address:100 N HOWARD ST STE R
City: City of Spokane
State: Washington 99201
Country: United States
Website: https://www.avaccess.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AV Access Launches BizEye P30: A 4K Dual-Lens PTZ Conference Camera with AI Tracking for Smarter Hybrid Meetings

Graft-Versus Host Disease Market Set for Robust Expansion Through 2034, DelveInsight Reports | CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics., Novartis

The Key Graft-Versus-Host Disease Companies in the market include – CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others.

 

The Graft-Versus-Host Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graft-Versus-Host Disease pipeline products will significantly revolutionize the Graft-Versus-Host Disease market dynamics.

 

DelveInsight’s “Graft-Versus-Host Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Graft-Versus-Host Disease, historical and forecasted epidemiology as well as the Graft-Versus-Host Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Graft-Versus-Host Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graft-Versus-Host Disease Market Forecast

 

Some of the key facts of the Graft-Versus-Host Disease Market Report:

  • The Graft-Versus-Host Disease market size was valued ~USD 1,301 million in 2023 and is anticipated to grow with a significant CAGR of 8.2% during the study period (2020-2034).

  • In June 2025, According to phase 3 BM12 CAST trial (ACTRN12618000505202) results presented at the 2025 European Hematology Association Congress, combining cyclophosphamide with cyclosporin, a calcineurin inhibitor, significantly enhanced graft-versus-host disease (GVHD)–free relapse-free survival (RFS) compared to standard prophylaxis in patients with aggressive blood cancers undergoing stem cell transplants from matched related donors with either reduced-intensity or myeloablative conditioning.

  • In March 2025, Signal12, Inc., a clinical-stage company specializing in ophthalmic pharmaceuticals, announced it has reached an agreement with the FDA regarding its Phase 3 clinical trial plan for Pro-ocular™—an innovative, drop-free treatment designed to transform care for ocular Graft-versus-Host Disease (oGvHD).

  • In December 2024, The FDA approved Mesoblast’s cell therapy, Ryoncil, for the treatment of graft-versus-host disease (GvHD) following stem cell or bone marrow transplantation. Ryoncil becomes the first mesenchymal stromal cell therapy authorized for use in pediatric patients as young as two months whose GvHD has not improved with standard steroid treatments.

  • In August 2024, AstraZeneca’s IMFINZI (durvalumab) has been approved by the FDA for treating adult patients with resectable early-stage (IIA–IIIB) non-small cell lung cancer (NSCLC) that lacks known EGFR mutations or ALK rearrangements. The approved regimen involves using IMFINZI alongside neoadjuvant chemotherapy prior to surgery, followed by IMFINZI as a standalone adjuvant therapy post-surgery.

  • In 2023, the Graft Versus Host Disease treatment market in the US was valued at around USD 920 million and is expected to grow further with the introduction of new and emerging therapies.

  • In 2023, the combined Graft Versus Host Disease market size for the EU4 and the UK was estimated at about USD 252 million, representing nearly 19% of the total market revenue across the 7MM.

  • In 2023, Germany led the Graft Versus Host Disease Treatment Market within the EU4 and the UK, generating approximately USD 98 million. France was next with about USD 41 million, and the UK reported nearly USD 40 million.

  • In 2023, Japan’s Graft Versus Host Disease Treatment Market Size was estimated at around USD 130 million and is expected to grow throughout the forecast period (2025-2034).

  • It is estimated that REZUROCK will generate around USD 173 million by 2034 across the 7MM.

  • DelveInsight estimates that in 2023, there were around 52,000 cases of Graft Versus Host Disease (GVHD) across the 7MM. The United States contributed to about 45% of these cases, while the EU4 countries and the UK collectively made up nearly 39%. Japan accounted for the remaining 16%.

  • According to DelveInsight’s epidemiological model, around 57,000 allogeneic transplants and nearly 52,000 Graft Versus Host Disease (GVHD) cases were reported across the 7MM in 2023. These numbers are projected to rise by 2034.

  • In 2023, the United States recorded the highest number of Graft Versus Host Disease cases among the 7MM, with around 24,000 cases, and this count is anticipated to increase by 2034.

  • In 2023, Germany had the highest number of Graft Versus Host Disease cases among the EU4 and the UK, with an estimated 8,000 cases. Italy and France followed closely, each reporting around 3,000 cases, while Spain recorded the fewest, with approximately 2,700 cases.

  • In 2023, the United States recorded nearly 5,000 new cases of Graft Versus Host Disease, along with an estimated 18,000 prevalent cases accumulated over a five-year period.

  • In 2023, Germany documented roughly 900 Graft Versus Host Disease cases affecting the skin, around 400 involving the liver, and nearly 800 cases impacting the gastrointestinal tract.

  • Key Graft-Versus-Host Disease Companies: CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others

  • Key Graft-Versus-Host Disease Therapies: ZEMAIRA (CSL 964, alpha-1 antitrypsin), EQ001 (itolizumab; Bmab600), MaaT013, RGI-2001, Defibrotide, Ibrutinib, Panobinostat (LBH589), Natalizumab, Methoxsalen, Prograf, Prochymal®, Abatacept, RGI-2001, Axatilimab, Ruxolitinib, and others

  • In the United States in 2022, roughly 4,780 cases of acute Graft-versus-host disease (aGvHD) and approximately 17,210 cases of chronic Graft-versus-host disease (cGvHD) received first-line treatment. Projections suggest an anticipated increase in these cases by the year 2034.

  • The Graft-Versus-Host Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graft-Versus-Host Disease pipeline products will significantly revolutionize the Graft-Versus-Host Disease market dynamics.

 

Graft-Versus-Host Disease Overview

Graft-Versus-Host Disease (GVHD) is a condition that occurs after a bone marrow or stem cell transplant in which the donated (graft) immune cells attack the recipient’s (host) body tissues. This reaction happens because the donor’s immune cells recognize the recipient’s cells as foreign and initiate an immune response against them.

 

Get a Free sample for the Graft-Versus-Host Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market

 

Graft-Versus-Host Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Graft-Versus-Host Disease Epidemiology Segmentation:

The Graft-Versus-Host Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Graft-Versus-Host Disease

  • Prevalent Cases of Graft-Versus-Host Disease by severity

  • Gender-specific Prevalence of Graft-Versus-Host Disease

  • Diagnosed Cases of Episodic and Chronic Graft-Versus-Host Disease

 

Download the report to understand which factors are driving Graft-Versus-Host Disease epidemiology trends @ Graft-Versus-Host Disease Epidemiology Forecast

 

Graft-Versus-Host Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graft-Versus-Host Disease market or expected to get launched during the study period. The analysis covers Graft-Versus-Host Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Graft-Versus-Host Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Graft-Versus-Host Disease Therapies and Key Companies

  • JAKAFI MOA/JAKAVI (ruxolitinib): Incyte

  • IMBRUVICA (ibrutinib): Pharmacyclics (acquired by AbbVie)/ Janssen

  • ZEMAIRA (CSL 964, alpha-1 antitrypsin): CSL Behring

  • EQ001 (itolizumab; Bmab600): Equillium/Biocon

  • CSL 964 AAT (zemaira): CSL Behring

  • MaaT013: MaaT Pharma

  • RGI-2001: Regimmune

  • Defibrotide: Jazz Pharmaceuticals

  • Ibrutinib: Pharmacyclics LLC.

  • Panobinostat (LBH589): Novartis

  • Natalizumab: Biogen

  • Methoxsalen: Mallinckrodt

  • Prograf: Astellas Pharma

  • Prochymal®: Mesoblast, Inc.

  • Abatacept: Thrasher Research Fund

  • RGI-2001: Regimmune Corporation

  • Axatilimab: Syndax Pharmaceutical

  • Ruxolitinib: Novartis

 

Discover more about therapies set to grab major Graft-Versus-Host Disease market share @ Graft-Versus-Host Disease Treatment Landscape

 

Graft-Versus-Host Disease Market Strengths

  • Pipeline of GvHD is very robust and several late stage assets are expected to enter in to the market very soon. GvHD pipeline consists of small molecules, monoclonal and Bi-specific antibody, stem cell therapy, recombinant fusion protein etc. which will provide the patients and physicians more options in future.

 

Graft-Versus-Host Disease Market Opportunities

  • Several upcoming therapies have received Orphan designations, therapies can get accelerated approval time, 7 years of market exclusivity in the US, clinical trials subsidies and reduced regulatory fees and others. Company can also go for premium pricing as well.

 

Scope of the Graft-Versus-Host Disease Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Graft-Versus-Host Disease Companies: CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others

  • Key Graft-Versus-Host Disease Therapies: ZEMAIRA (CSL 964, alpha-1 antitrypsin), EQ001 (itolizumab; Bmab600), MaaT013, RGI-2001, Defibrotide, Ibrutinib, Panobinostat (LBH589), Natalizumab, Methoxsalen, Prograf, Prochymal®, Abatacept, RGI-2001, Axatilimab, Ruxolitinib, and others

  • Graft-Versus-Host Disease Therapeutic Assessment: Graft-Versus-Host Disease current marketed and Graft-Versus-Host Disease emerging therapies

  • Graft-Versus-Host Disease Market Dynamics: Graft-Versus-Host Disease market drivers and Graft-Versus-Host Disease market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Graft-Versus-Host Disease Unmet Needs, KOL’s views, Analyst’s views, Graft-Versus-Host Disease Market Access and Reimbursement

 

To know more about Graft-Versus-Host Disease companies working in the treatment market, visit @ Graft-Versus-Host Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Graft-Versus-Host Disease Market Report Introduction

2. Executive Summary for Graft-Versus-Host Disease

3. SWOT analysis of Graft-Versus-Host Disease

4. Graft-Versus-Host Disease Patient Share (%) Overview at a Glance

5. Graft-Versus-Host Disease Market Overview at a Glance

6. Graft-Versus-Host Disease Disease Background and Overview

7. Graft-Versus-Host Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Graft-Versus-Host Disease

9. Graft-Versus-Host Disease Current Treatment and Medical Practices

10. Graft-Versus-Host Disease Unmet Needs

11. Graft-Versus-Host Disease Emerging Therapies

12. Graft-Versus-Host Disease Market Outlook

13. Country-Wise Graft-Versus-Host Disease Market Analysis (2020–2034)

14. Graft-Versus-Host Disease Market Access and Reimbursement of Therapies

15. Graft-Versus-Host Disease Market Drivers

16. Graft-Versus-Host Disease Market Barriers

17. Graft-Versus-Host Disease Appendix

18. Graft-Versus-Host Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Graft-Versus Host Disease Market Set for Robust Expansion Through 2034, DelveInsight Reports | CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics., Novartis

€6.4 Million in Signed Contracts Across Multiple Countries in 2025 First Half from High Growth Global Technology Smart City Developer: Affluence Corporation (Symbol: AFFU)

€6.4 Million in Signed Contracts Across Multiple Countries in 2025 First Half from High Growth Global Technology Smart City Developer: Affluence Corporation (Symbol: AFFU)
$AFFU Expanding into United States Projects in Conjunction with Financial Optimization Initiative
  • Diversified Global Technology Company Focused on Smart City and Industry Software plus Innovative Solutions.
  • Projects Capitalize on IoT, AI, 5G and Edge Technologies.
  • AFFU Subsidiaries Secured Over €6.4 Million in Signed Contracts, with €2.95 Million Already Billed as of June 30th.
  • New Strategic Focus on Business Development in the United States.
  • Multiple U.S. Based Projects Already Being Developed and Expansion Efforts Expected to Accelerate in the Second Half of the Year.
  • Projects Across Europe, Asia and Central Africa Reflect Capacity to Deliver in Key Verticals Such as Smart Cities, Security and Digital Transformation.
  • Key Customers and Partners, Including Major European Defense Integrators, Leading Global Sports Organizations and Asian Government Security Agencies.
  • New President with Experience and Success in Private Equity, Capital Formation, M&A and Real Estate Development Across The USA, Europe and Latin America.

Affluence Corporation (AFFU.OTCID) is a diversified global technology company focused on smart city and industry software and innovative solutions that capitalize on IoT, AI, 5G and edge technologies. AFFU is investing in mid-market businesses to create a cohesive unit which brings together technology for the next generation of internet.

Strategic Growth, U.S. Expansion and Financial Reset

On July 22nd AFFU issued a letter to its shareholders from the newly appointed President, Oscar Brito which included the following:

In the first half of 2025, AFFU operating subsidiaries, secured over €6.4 million in signed contracts across Europe, Asia, and Central Africa. This commercial traction proves that AFFU technology is not only viable-it is in demand globally.

Starting this quarter, AFFU is launching a renewed focus on the U.S. market. Multiple domestic projects are already underway, with expectations that the U.S. pipeline to grow significantly in the second half of the year.

AFFU near-term goals include:

Expanding U.S. operations and onboarding new municipal and enterprise clients.

Launching acquisitions that extend our presence into adjacent high-margin verticals.

Re-engaging the investment community with clarity, transparency, and results.

Over €6.4 Million in Signed Contracts for H1 2025, Confirming Positive Momentum and Strategic Focus on U.S. Expansion

On July 7th AFFU shared a mid-year update confirming strong commercial progress across its portfolio companies, MTi (Mingothings) and OneMind Technologies.

As of the end of June 2025, the AFFU group has secured over €6.4 million in signed contracts, with €2.95 million already billed. This figure consolidates deals closed by AFFU subsidiaries in the first half of the year. It reflects strong market traction across Smart Cities, Industrial IoT, and Security Infrastructure verticals.

Looking ahead to H2 2025, the AFFU group will maintain its commercial momentum while placing a strategic focus on business development in the United States. Multiple U.S.-based projects are already being developed, and expansion efforts are expected to accelerate in the second half of the year.

AFFU remains fully committed to its roadmap and management expects to continue delivering measurable results and updates as it expands across global markets.

About Mingothings SLU

Mingothings SLU (“MTi”) is a trusted specialist in integrated IoT solutions and data analytics for smart cities and connected industries. With expertise in real-time data processing, sensor integration, and adaptable IoT platforms, MTi provides innovative solutions designed to maximize efficiency, sustainability, and operational performance in diverse IoT applications.

For more information visit: https://www.mingothings.com/.

About OneMind Technologies SLU

OneMind Technologies, based in Barcelona, Spain, is a recognized provider of IoT, Smart City, and Security Command and Control solutions. With its innovative OneMind platform, OMT enables cities and industries to optimize operations, enhance public safety, and support sustainable development.

For more information visit: https://onemindng.com/.

AFFU Subsidiary MTi Secures Over €3 Million in New Contracts Across Europe, Asia, and Central Africa

On June 27th AFFU announced that its subsidiary Mingothings International (MTi) has successfully secured multiple new contracts in June 2025, further strengthening its growth trajectory.

MTi has finalized commercial agreements exceeding a total value of €3 million, spanning projects across Europe, Asia, and Central Africa for AFFU. These contracts reflect MTi’s ongoing capacity to deliver advanced technology solutions in key verticals such as Smart Cities, Security, and Digital Transformation.

Among these recent AFFU wins are projects involving key customers and partners, including major European defense integrators, leading global sports organizations, and Asian government security agencies.

The new contracts are fully aligned with AFFU strategic priorities for 2025, demonstrating its portfolio companies’ capability to expand geographically while addressing critical infrastructure challenges in both public and private sectors.

Affluence Corporation Appoints Oscar Brito as President

On June 12th AFFU announced the appointment of Oscar Brito as President of the Company with immediate effect. His appointment is a crucial step in the planned acquisition strategy to scale and profitably grow the group in the Smart City and Connected Industries IoT space.

Mr Brito brings a wealth of experience in private equity, capital formation, mergers and acquisitions, and real estate development across the United States, Europe and Latin America to AFFU. He has played a key role in raising over $600 million in funding for projects and companies across real estate, telecommunications, and information technology sectors. As a principal and co-investor, he has additionally raised approximately $400 million in capital across a variety of industries, including value-added telecom and telecom infrastructure investments. His expertise lies in identifying high-growth, opportunistic investments and structuring complex financial transactions to support their execution and growth.

Most recently, Mr Brito was the co-founder, Member of the Board and an active investor in iQSTEL Inc, (Nasdaq: IQST) a US based telecommunications company generating over $300 million in annual revenue. iQSTEL has become a recognized player in the international telecom market, with a focus on next-generation services and infrastructure.

For more information on $AFFU visit: https://affucorp.com

Websites:

Home

https://onemindng.com/

Yahoo: https://finance.yahoo.com/quote/AFFU

Twitter: https://twitter.com/AffuCo

LinkedIn: https://www.linkedin.com/company/affu-corp

Facebook: https://www.facebook.com/AffuCorp/

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: Affluence Corporation (AFFU.OTCID)
Contact Person: Oscar Brito, President
Email: Send Email
Phone: +1 720-295-6409
Address:875 North Michigan Avenue Suite 3100
City: Chicago
State: IL 60611
Country: United States
Website: https://affucorp.com

Mixed Martial Arts Group Ltd. Is Turning Fans Into a Market (NYSE American: MMA)

Mixed Martial Arts Group Ltd. (NYSE American: MMA) isn’t just riding the momentum of combat sports; it’s building the engine that powers it. The vision is bold: take the raw energy of the fight world and channel it into a connected, thriving economy where fans become participants, participants become loyal customers, and loyalty fuels growth at every level. This isn’t a side hustle to the sport. This is the business of participation, and MMA is owning it.

The journey begins where the sport has its heartbeat, inside the gyms, academies, and training facilities where the next champions are forged. Through its BJJLink platform and integrated ecosystem, MMA delivers the digital backbone martial arts has always needed. Membership management, billing, scheduling, communications, and analytics are all tied to a member-facing experience that keeps students engaged and connected. By bringing structure to a space that’s long been fragmented, MMA is turning every academy into an accelerant for its expanding network. The results are already making a financial impact.

For the seven months ended July 31, BJJLink posted 128% annualized revenue growth, with SaaS subscription revenue climbing 188% annualized. These aren’t just statistics. They’re real-world validation that MMA’s model is resonating: academies are onboarding faster, students are staying longer, and upsells are becoming second nature. This kind of momentum carries real weight, and it’s paving the way for rapid scaling.

Scaling Through Powerful Partnerships

One of the biggest drivers of that scale is UFC GYM, which has selected BJJLink as the software backbone for its Brazilian jiu-jitsu franchise expansion. With forty-five new academies set to open in 2025, MMA has a built-in pipeline of premium locations ready to run on its platform. This partnership accelerates adoption, shortens sales cycles, and locks in recurring, high-margin revenue. More than just a growth opportunity, the UFC GYM rollout is a catalyst that propels the entire business model forward.

The timing couldn’t be better. The UFC’s new U.S. media rights deal, beginning in 2026, will bring unprecedented visibility to the sport. As more fans are drawn in, many will look to participate rather than just watch. MMA is positioned to capture that moment, converting curiosity into commitment and turning new participants into long-term members of its ecosystem.

Adding to that firepower is Conor McGregor, an investor, major shareholder, and global sports icon whose influence extends far beyond the octagon. One of the most recognized names in athletics and a dominant presence on social media, his involvement boosts MMA’s credibility, broadens its cultural reach, and unlocks access to partnerships, sponsorships, and media opportunities few can match.

Strength in Leadership and Vision

Alongside McGregor, MMA has added Laura Sanko to its Board of Directors. One of the UFC’s most recognizable voices behind the mic, she draws on her experience as a former professional mixed martial artist and black belt in Brazilian jiu-jitsu. Sanko’s blend of competitive credentials, business perspective, and authentic connection to the martial arts community makes her a strong asset as MMA advances its expansion plans.

MMA’s growth engine runs on more than market momentum; it’s fueled by leaders with skin in the game. In June, CEO Nick Langton and Chairman Vaughn Taylor converted $250,000 in prior loans into equity, directly tying their personal stakes to MMA’s future. This move came alongside a $5 million underwritten offering dedicated to product development, marketing, and scaling. The result is a company with the capital, leadership commitment, and operational focus to execute without compromise.

There’s no guesswork here. The strategy is deliberate and scalable. MMA is growing from a position of strength by securing a dominant position in Brazilian jiu-jitsu academies, where digital tools can quickly become essential and, just as importantly, serve as value drivers for daily operations .From that foundation, MMA is set to push into additional martial arts disciplines while stacking on complementary services like e-commerce, athlete management, and advanced engagement platforms. Each new layer strengthens the ecosystem and unlocks fresh revenue streams.

Shaping the Future of Martial Arts

Momentum, timing, leadership, and vision are aligning now. BJJLink’s growth curve is steepening, the UFC GYM partnership is about to inject scale, and the board features figures who combine credibility with market reach. Shareholders, insiders, and strategic partners are united around a single goal: transforming martial arts from a collection of disconnected businesses into a connected, monetizable, and sustainable global ecosystem.

Mixed Martial Arts Group Ltd. isn’t here to watch the sport evolve. It’s here to shape it. From the first gym signup to the biggest stages in the world, MMA is building the rails for a new era of participation. The fight world has always been defined by energy, passion, and commitment. With MMA’s platform in place, it’s about to be defined by connection, scale, and growth, and that’s a win every stakeholder can share.

 

Disclaimers: This presentation has been created by Hawk Point Media Group, Llc. (HPM) and is responsible for the production and distribution of this content. This presentation should be considered and explicitly regarded as sponsored content. Hawk Point Media Group, LLC. has been compensated five thousand dollars via wire transfer from IR Agency, Inc. to create and syndicate this content as part of a more extensive digital marketing program by IR Agency, Inc. Accordingly, this content may be reused and syndicated beyond the channels used by Hawk Point Media, LLC. This disclaimer and the link to the broader disclosures must be part of all reproductions. The compensation received creates a conflict of interest because the content presented may only provide a favorable viewpoint of the company featured. The contributors do NOT buy and sell securities before and after any article, report, or publication. HPM holds ZERO shares and has never owned stock in Mixed Martial Arts Group Ltd. The information in this video, article, and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you to conduct a complete and independent investigation of the respective companies and consider all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Never take opinions, articles presented, or content provided as the sole reason to invest in any featured company. Investors must always perform their own due diligence before investing in any publicly traded company and understand the risks involved, including losing their entire investment.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mixed Martial Arts Group Ltd. Is Turning Fans Into a Market (NYSE American: MMA)

Steller Firearms Expands Trusted Gun Storage Services to Calgary and Surrounding Areas

“Steller Firearms Management & Storage”
Steller Firearms Management & Storage, a leader in secure firearm management in Western Canada, has expanded its trusted, RCMP-compliant storage services to Calgary and surrounding communities. Already well-established in Vancouver, the company now offers Alberta gun owners secure short- and long-term storage, firearm holding for legal or estate purposes, purchase and transfer support, and expert consulting.

Steller Firearms Management & Storage, Western Canada’s leader in secure and professional firearm storage, is proud to announce the expansion of its RCMP-compliant Storage Services to Calgary, Alberta, and surrounding communities. With a well-established presence in Vancouver, British Columbia, Steller Firearms is now positioned to serve a broader network of responsible gun owners, collectors, estate managers, and legal professionals across Alberta.

As firearms ownership continues to rise across Western Canada, so does the demand for safe, discreet, and fully compliant gun storage services. Steller Firearms is answering that call with a facility in Calgary equipped to meet the same high standards of security, professionalism, and regulatory compliance that have defined its operations in British Columbia.

“We’re proud to extend our services into Alberta and help meet the increasing demand for trusted firearm management,” said a spokesperson for Steller Firearms. “Our Calgary expansion reinforces our commitment to public safety, legal compliance, and peace of mind for gun owners.”

Serving Alberta’s Gun Owners With Trusted Firearm Storage Solutions

Steller Firearms’ Calgary operations will provide a full spectrum of firearm management services, including:

  • Secure Firearm Storage – short-term and long-term storage options in a climate-controlled, highly secure, monitored facility.

  • Firearm Holding – for individuals facing legal restrictions, estate transitions, or court-ordered removals.

  • Firearm Purchasing & Transfer Support – assistance in purchasing, transferring, or safely disposing of firearms.

  • Firearms Consulting – tailored advice for estate planning, legal proceedings, inheritance, or voluntary surrender.

  • RCMP-Compliant Firearm Storage – full adherence to all federal regulations, including restricted and prohibited firearm categories.

All services are designed for maximum discretion and legal compliance. Facilities are equipped with high-end surveillance, biometric access controls, and alarm systems, offering clients the utmost in security and privacy.

“From gun collectors to estate lawyers, our clients need more than just storage—they need professional management,” said another company representative. “We act as a trusted partner in navigating the complex world of firearm ownership and compliance.”

A Growing Need for Secure, Professional Firearm Management in Alberta

Firearms ownership in Alberta has become more complicated in recent years. Legal responsibilities around ownership, transfer, and storage have become more complex. For gun owners in transition—due to travel, life changes, legal proceedings, or estate matters—secure firearm storage is often a necessity rather than a convenience.

Steller Firearms provides an essential solution by offering:

  • RCMP-approved secure storage options

  • Legal support and consulting services to help clients navigate federal and provincial firearm laws

  • Firearm transfer and transportation services following current Canadian laws

By expanding to Calgary, the company offers its specialized expertise to gun owners who need help managing their firearms responsibly and safely, without compromising their rights or privacy.

“Whether you’re an individual needing temporary gun storage, a family managing a firearm inheritance, or a legal team handling an estate, we provide clear, compliant, and secure solutions tailored to your needs,” the spokesperson added.

Discretion, Compliance, and Community Trust

Steller Firearms has built its reputation on integrity, professionalism, and unwavering compliance with Canada’s complex firearms regulations. As firearms regulations evolve, clients can count on Steller to remain up to date with the latest legal requirements and best practices in firearms management.

The company works closely with:

  • Local and provincial law enforcement agencies

  • Legal professionals and estate planners

  • Collectors and shooting sports communities

  • Private citizens and families

The new Calgary facility will offer secure storage, private transfer appointments, and discreet consulting services to ensure every client feels supported and informed.

Commitment to Firearm Owners Across Western Canada

This expansion is a major step in Steller Firearms’ strategic plan to provide regional coverage across Western Canada. By building out a network of facilities in key urban centres, Steller aims to support responsible firearm ownership, reduce the risk of improper storage, and give gun owners options that are compliant, convenient, and confidential.

“Gun owners deserve access to professional, secure services that respect both their rights and the law,” the representative said. “That’s what we offer at Steller Firearms—trusted gun storage and expert consulting you can rely on.”

Contact & Additional Information

To learn more about Steller Firearms Management & Storage’s new Calgary services or to book a confidential consultation, visit our website or contact info@stellermgmt.com

About Steller Firearms Management & Storage

Steller Firearms is Western Canada’s trusted source for secure, RCMP-compliant firearm storage, consulting, and legal transfer services. With operations in British Columbia and Alberta, the company serves gun owners, collectors, legal professionals, and estate managers with professional, discreet, and fully compliant storage solutions.

Media Contact
Company Name: Steller Firearms Management & Storage
Email: Send Email
Phone: 604-305-4612
Address:#330055 West Vancouver RPO
City: West Vancouver
State: British Columbia
Country: Canada
Website: https://www.stellermgmt.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Steller Firearms Expands Trusted Gun Storage Services to Calgary and Surrounding Areas

Vinx Pest Control Expands Comprehensive Services in Columbia, SC

Vinx Pest Control Expands Comprehensive Services in Columbia, SC
Vinx Pest Control is a trusted provider of professional pest management solutions in Columbia, SC. Specializing in safe, effective treatments for homes and businesses, Vinx offers expert services for insects, rodents, and more. With a focus on prevention and long-term results, Vinx ensures clean, pest-free environments year-round.

Columbia, SC – Vinx Pest Control, with a growing demand for safe and effective pest treatment solutions, the company continues to set the standard in both residential and commercial sectors.

Tailored Pest Management for Homes and Businesses

Vinx Pest Control provides targeted solutions to address a wide range of infestations, including termites, ants, roaches, rodents, and more. Every treatment is tailored to suit the needs of the structure and pest type, ensuring efficient and lasting results. As a top-rated provider of Pest Control in Columbia, the company remains committed to safeguarding properties with precision-driven service.

Eco-Friendly and Safe Pest Solutions

In response to increased awareness of environmental safety, Vinx Pest Control utilizes eco-conscious products that are both child- and pet-safe. These methods minimize risk to non-target species while maintaining a high level of effectiveness. Customers seeking responsible Pest Control Services in Columbia find confidence in Vinx’s approach.

Trusted by the Columbia Community

Known for its transparent communication and industry expertise, Vinx Pest Control has built a solid reputation throughout the Columbia area. Residents and business owners consistently rely on the team for proactive prevention and thorough Pest Removal in Columbia when infestations occur.

About Vinx Pest Control

Vinx Pest Control continues to deliver on its mission of providing pest-free peace of mind across Columbia. For more information about services or scheduling, visit their official website.

Media Contact
Company Name: Vinx Pest Control
Contact Person: Ryan Marshall
Email: Send Email
Phone: (803) 925-8469
Address:1410 St Andrews Rd Ste 230
City: Columbia
State: SC 29210
Country: United States
Website: https://vinxpestcontrol.com/columbia-pest-control/?utm_source=google&utm_medium=gbp_columbia&utm_campaign=google_business_profile

Apps4.Pro Launches the Most Comprehensive Microsoft 365 Migration Tool

Apps4.Pro, a leader in enterprise productivity solutions, proudly announces the enhanced release of its flagship Microsoft 365 Migration Tool, empowering IT teams, MSPs, and enterprises worldwide to perform seamless tenant-to-tenant migrations across all Microsoft 365 workloads. The Apps4.Pro Migration Manager is designed to simplify even the most complex Office 365 migration scenarios — from Exchange Online migration to SharePoint Online migration, Teams migration, and beyond.

With over 15,000+ customers globally, including Fortune 500 companies and high-growth startups, Apps4.Pro is recognized as the only migration software capable of flawlessly transferring workloads like Viva Engage (Yammer), Power Automate, and Power BI between tenants with zero data loss.

More information can be found at https://apps4.pro/migration-manager.

Addressing a Critical Need for Hassle-Free Microsoft 365 Tenant Migration

In today’s fast-paced digital environment, organizations often face the need to consolidate, restructure, or move workloads between Microsoft 365 tenants — due to mergers, acquisitions, compliance requirements, or infrastructure optimization. However, tenant-to-tenant migration is notoriously complex, with high risks of downtime, data loss, and configuration errors.

Apps4.Pro Migration Manager eliminates these challenges by delivering:

  • 100% Secure Transfers with enterprise-grade encryption.

  • Faster, Automated Execution to reduce downtime.

  • End-to-End Migration Coverage across all Office 365 workloads.

  • Expert Post-Migration Support to ensure business continuity.

“Our mission has always been to remove the uncertainty from Microsoft 365 migrations,” said [Spokesperson Name], [Position] at Apps4.Pro. “We’ve combined cutting-edge automation with hands-on expert guidance to ensure organizations can execute migrations without stress, delays, or data integrity issues.”

Comprehensive Workload Support – All in One Platform

Unlike single-solution tools, Apps4.Pro Migration Manager is a complete M365 migration software capable of handling every major Microsoft 365 workload:

  • Exchange Online Migration – Mailboxes, tasks, calendars, server-side rules, and group mailboxes.

  • SharePoint Online Migration – Sites, lists, libraries, permissions, and metadata.

  • Microsoft Teams Migration Tool – Teams chats, channels (private/shared), EDU migrations, attachments, and reactions.

  • Microsoft Planner Migration – Plans, attachments, comments, and task assignments.

  • Viva Engage (Yammer) Migration – Internal/external networks, conversations, files, and admin settings.

  • Microsoft Bookings Migration – Appointments, services, staff, and customer data.

  • OneDrive for Business Migration – Files, folders, and permissions with no limitations.

  • Power Automate Migration – Automated connector mapping for flow transfers.

  • Microsoft Forms Migration – User/group forms with complete responses.

  • Microsoft Power BI Migration – Workspaces, datasets, dashboards, and permissions.

This Office 365 migration tool ensures not only that data moves quickly and securely, but also that metadata, permissions, and version histories remain fully intact.

Streamlined Three-Step Migration Process

Apps4.Pro has redefined the migration experience with its three-step process:

  1. Pre-Migration Analysis – Generate a free inventory report to assess readiness and identify risks.

  2. Automated Migration – Run secure, unattended migrations with multi-threaded processing.

  3. Post-Migration Validation – Verify data accuracy, permissions, and configurations for a flawless handover.

This structured approach ensures predictable timelines and minimal disruption to end-users.

Why IT Teams, MSPs, and Enterprises Trust Apps4.Pro

1. Zero Data Loss Guarantee Data integrity is at the heart of every migration. Apps4.Pro’s Microsoft 365 migration manager preserves structure, security settings, and compliance standards.

2. Scalability & Flexibility From small businesses to enterprise-scale moves, the Office 365 tenant migration platform supports multi-VM deployment, complex configurations, and high-volume workloads.

3. Proven Global Track Record Trusted by organizations across healthcare, manufacturing, finance, education, and technology sectors, Apps4.Pro delivers measurable results and consistent reliability.

4. Human-Centered Support Beyond software, Apps4.Pro offers dedicated migration experts who stay engaged before, during, and after the project — ensuring every migration is a success.

Customer Success Stories – Real-World Impact

ServiceNet, USA – “The Planner migration was seamless. Apps4.Pro saved us countless hours while ensuring every attachment and comment was preserved,” said Denzel Dalton, Computer Technician.

Resillion, Global IT – “Migrating private Teams chats was a challenge until we found Apps4.Pro. The structured automation preserved entire histories without loss,” said Venkatesh Narayanan, Head of Global IT.

Petronas – “Merging Yammer networks with full content retention was critical. Apps4.Pro handled it flawlessly,” noted Mohamad Nuzul Izwan, Group Business Technology.

MCM Consulting, Canada – “We migrated over 1,200 Planner plans and multiple workloads successfully. Apps4.Pro is now our go-to migration partner,” said Mike Maadarani, Cloud Solutions Architect.

Setting a New Standard in M365 Migration Software

While other tools often specialize in one or two workloads, Apps4.Pro stands apart as a full-spectrum Office 365 migration tool — capable of executing:

  • High-volume, parallel task processing for faster cutovers.

  • Geo-move support for Microsoft’s regional data center shifts.

  • Compliance-driven migrations meeting industry security standards.

  • Custom migration strategies tailored to each organization’s needs.

The software is constantly updated to align with Microsoft’s evolving API landscape, ensuring compatibility and future-readiness.

Free Trial, Live Demo & 24/7 Support

To help organizations experience its capabilities risk-free, Apps4.Pro offers:

  • Free Trial – No Credit Card Required Test-drive the migration manager in your own environment.

  • Live 1-on-1 Demo Sessions Explore the platform with real migration scenarios and expert Q&A.

  • 24/7 Global Support Round-the-clock consulting for planning, execution, and validation.

About Apps4.Pro

Based in Tirunelveli, India, Apps4.Pro is a trusted name in enterprise productivity and migration solutions. Serving more than 15,000 customers across industries, the company specializes in Microsoft 365 tools, integrations, and migration software. Its flagship product, Apps4.Pro Migration Manager, is setting new benchmarks for secure, scalable, and stress-free Microsoft 365 migrations.

Visit https://apps4.pro/migration-manager for more details.

Media Contact
Company Name: Apps4.Pro
Email: Send Email
Country: India
Website: https://apps4.pro/migration-manager

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Apps4.Pro Launches the Most Comprehensive Microsoft 365 Migration Tool

Aviation Game-Changer: Sky-Blue Sets New Standard for Sustainable Inflight Service

Sky-Blue, a leading designer and supplier of bespoke inflight products, is setting new standards for the global airline industry with innovative, sustainable solutions that elevate the passenger experience. By combining premium craftsmanship with eco-conscious design, Sky-Blue partners with airlines worldwide to create memorable onboard experiences while reducing environmental impact.

Reading, Berkshire, UK – August 13, 2025 – Sky-Blue, a leading designer and supplier of bespoke inflight products, is setting new standards for the global airline industry with innovative, sustainable solutions that elevate the passenger experience. By combining premium craftsmanship with eco-conscious design, Sky-Blue partners with airlines worldwide to create memorable onboard experiences while reducing environmental impact.

More information can be found at https://www.sky-blue.uk.

Taking Inflight Service to New Heights

Airline passengers expect more than just a journey—they expect a seamless blend of comfort, style, and service. Sky-Blue delivers exactly that. With a commitment to bespoke design and sourcing solutions, the company collaborates closely with airline partners to bring their brand visions to life, from first-class dining elegance to eco-friendly economy cabin essentials.

“Our mission is simple,” says the Sky-Blue team. “We help airlines stand out in the sky by delivering products that are beautiful, functional, and sustainable—without compromising on quality or passenger comfort.”

A Comprehensive Product Range for Every Cabin

Sky-Blue’s curated product line serves every aspect of the inflight experience, offering tailored solutions for First Class, Business, Premium Economy, and Economy cabins. The extensive portfolio includes:

  • Cutleries – From sleek stainless steel for premium cabins to lightweight, sustainable options for economy service.

  • Tableware – Plates, bowls, and serving dishes designed for practicality and presentation.

  • Glassware – Elegant wine, champagne, spirits, and stemless glasses to enhance the beverage experience.

  • Serving Items – Functional and stylish jugs, tongs, and trays for smooth inflight service.

  • Textiles – Luxurious yet durable fabrics, including napkins, tablecloths, and bespoke amenity kits.

  • Disposables – Eco-conscious options crafted from recyclable and compostable materials.

Every piece is designed with the dual goals of aesthetic excellence and operational efficiency, ensuring cabin crew can deliver exceptional service with ease.

Bespoke Design: Where Creativity Meets Functionality

What sets Sky-Blue apart is its ability to custom-create products that reflect an airline’s unique brand identity. The design team works hand-in-hand with clients, turning ideas into reality through tailored materials, finishes, and branding options.

Whether it’s exclusive tableware for a luxury carrier’s first-class suite or practical, space-saving serving jugs for high-capacity flights, every project receives the same meticulous attention to detail.

“We believe every element of the inflight experience tells a story,” notes the design team. “Our role is to ensure that story aligns perfectly with the airline’s vision while meeting operational demands.”

Sustainability at the Core

In an era where environmental responsibility is paramount, Sky-Blue leads the way with eco-friendly design philosophies. The company prioritizes recyclable, biodegradable, and reusable materials to help reduce the aviation industry’s carbon footprint.

From biodegradable cutlery to textiles made from recycled fibers, Sky-Blue actively seeks innovative ways to minimize waste without compromising style or performance. This commitment ensures airline partners can meet both customer expectations and global sustainability goals.

Driving Innovation in the Aviation Industry

Sky-Blue’s passion for innovation is evident in its continuous research into new materials, designs, and service solutions. The company frequently introduces next-generation inflight products that improve passenger comfort, streamline crew operations, and extend product lifespan.

Recent innovations include:

  • Lightweight, shatter-resistant glassware that reduces onboard weight and fuel consumption.

  • Multi-functional serving items that save galley space while increasing efficiency.

  • Textiles with enhanced durability to withstand repeated commercial laundering, extending their lifecycle.

This forward-thinking approach positions Sky-Blue as a trusted partner for airlines seeking to future-proof their onboard offerings.

Global Reach, Personalised Service

While Sky-Blue is headquartered in Reading, Berkshire, its influence spans the globe. The company works with airlines of all sizes, from boutique regional carriers to some of the world’s largest international fleets. Despite its global reach, Sky-Blue maintains a personalised, relationship-driven approach to each project.

“Our strength lies in understanding each airline’s unique needs,” says the Sky-Blue team. “We are not just suppliers—we are partners invested in the airline’s success.”

Commitment to Quality

Every Sky-Blue product undergoes rigorous quality checks to ensure it meets the high standards demanded by the aviation sector. Durability, safety, and functionality are tested to withstand the unique conditions of inflight service—ensuring longevity and reliability.

Sky-Blue’s quality promise covers every product category, whether it’s a fine crystal champagne flute for first-class passengers or a compostable cup for eco-conscious travelers.

A Vision for the Future

Sky-Blue’s vision is to become the leading designer and supplier of recyclable and compostable inflight products for the global airline industry. With a focus on innovation, sustainability, and customer experience, the company is committed to redefining inflight service for a greener future.

This vision is supported by an ongoing investment in R&D, partnerships with sustainable material innovators, and a dedication to creating bespoke products that inspire passenger loyalty.

Customer-Centric Philosophy

From initial concept to final delivery, Sky-Blue ensures complete transparency, open communication, and exceptional service throughout the design and sourcing process. This customer-first philosophy has earned the company a reputation for reliability and trustworthiness in the competitive aviation supply market.

Contact Information

For airlines, catering companies, and aviation service providers looking to elevate their inflight experience, Sky-Blue offers a no-obligation consultation to explore bespoke solutions.

Contact Sky-Blue today:

  • Phone: +44 (0)118 958 9526

  • Email: info@sky-blue.uk

  • Address: Unit 2, Barrett Court, 70 Cardiff Road, Reading, Berkshire, RG1 8ED, UK

  • Website: www.sky-blue.uk


About Sky-Blue

Sky-Blue is a UK-based designer and supplier of premium inflight products, serving airlines across the globe with bespoke, sustainable solutions. Its comprehensive product range includes cutlery, tableware, glassware, textiles, serving items, and eco-friendly disposables. By blending cutting-edge design, functionality, and environmental responsibility, Sky-Blue helps airlines deliver memorable onboard experiences while reducing their carbon footprint.

Media Contact
Company Name: Sky Blue
Email: Send Email
Country: United Kingdom
Website: https://www.sky-blue.uk/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Aviation Game-Changer: Sky-Blue Sets New Standard for Sustainable Inflight Service